Compare · AVTR vs LAB
AVTR vs LAB
Side-by-side comparison of Avantor Inc. (AVTR) and Standard BioTools Inc. (LAB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AVTR and LAB operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- AVTR is the larger of the two at $6.25B, about 13.9x LAB ($448.9M).
- Over the past year, AVTR is down 27.2% and LAB is down 22.0% - LAB leads by 5.2 points.
- LAB has been more active in the news (10 items in the past 4 weeks vs 3 for AVTR).
- AVTR has more recent analyst coverage (25 ratings vs 5 for LAB).
- Company
- Avantor Inc.
- Standard BioTools Inc.
- Price
- $9.79+6.88%
- $0.85-26.11%
- Market cap
- $6.25B
- $448.9M
- 1M return
- +17.67%
- -15.82%
- 1Y return
- -27.24%
- -22.03%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- 2011
- News (4w)
- 3
- 10
- Recent ratings
- 25
- 5
Avantor Inc.
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, and clinical trial kits. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Standard BioTools Inc.
Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Standard BioTools Inc. has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
Latest AVTR
- Wolfe Research resumed coverage on Avantor with a new price target
- SEC Form SD filed by Avantor Inc.
- Avantor® Announces Gerard (Jerry) Porreca as Executive Vice President, Quality and Regulatory
- RBC Capital Mkts resumed coverage on Avantor with a new price target
- Avantor Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Murthy Mala was granted 25,270 shares, increasing direct ownership by 57% to 69,479 units (SEC Form 4)
- Director Lucier Gregory T was granted 25,270 shares and bought $83,200 worth of shares (10,000 units at $8.32), increasing direct ownership by 289% to 34,006 units (SEC Form 4)
- Director Dingemans Simon was granted 25,270 shares, increasing direct ownership by 406% to 31,495 units (SEC Form 4)
- Director Massaro Joseph R was granted 25,270 shares, increasing direct ownership by 48% to 77,408 units (SEC Form 4)
- Director Makin Louise was granted 25,270 shares, increasing direct ownership by 116% to 47,140 units (SEC Form 4)
Latest LAB
- SEC Form 425 filed by Standard BioTools Inc.
- Standard BioTools Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Changes in Control of Registrant, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Standard BioTools and Treeline Biosciences Announce Merger Agreement
- SEC Form 8-K filed by Standard BioTools Inc.
- Standard BioTools Inc. filed SEC Form 8-K: Leadership Update
- SEC Form SD filed by Standard BioTools Inc.
- Standard BioTools Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Chief Financial Officer Kim Hanjoon Alex covered exercise/tax liability with 18,871 shares, decreasing direct ownership by 0.68% to 2,760,530 units (SEC Form 4) (tax liability)
- SVP & Chief Business Officer Mackay Sean covered exercise/tax liability with 25,729 shares, decreasing direct ownership by 2% to 1,006,552 units (SEC Form 4) to satisfy tax liability
- President & CEO Egholm Michael covered exercise/tax liability with 97,626 shares, decreasing direct ownership by 1% to 6,597,956 units (SEC Form 4) (for withholding tax)